$LKFT

Lakefront Biotherapeutics (LKFT) announced that the U.S. FDA granted Orphan Drug Designation to gamgertamig for treating pemphigus, adding to prior designations for AIHA and ITP. The drug is in Phase 1b trials for autoimmune diseases, with expansion planned in 2027. Lakefront is developing gamgertamig with Gilead Sciences, aiming for registrational studies next year.

Lakefront Biotherapeutics (LKFT) reported half-year 2026 results and updated its business after completing its Ouro Medicines acquisition with Gilead in June. It forecast at least €1.6B dry powder after funding gamgertamig to first approval, and maintained ~€2B year-end cash and investments guidance, now including a €50M share repurchase. H1 2026 net revenues were €18.6M and net profit was €16.6M.

Lakefront Biotherapeutics (LKFT) reported that, under its June 9, 2026 share repurchase program, it bought back 108,645 of its ordinary shares between July 6 and July 10, 2026. The average price was €26.672 per share, totaling €2,897,722.65, with prices from €26.14 to €27.00. As of July 10 close, it held 412,401 treasury shares.

Lakefront Biotherapeutics NV (LKFT) said board member Dr. Paulo Fontoura resigned after being appointed Executive Vice President and Global Head of Research and Development Pharma at Sanofi SA, according to the company. Chair Gino Santini thanked him and said Lakefront expects to appoint a successor soon.

Lakefront Biotherapeutics NV (LKFT) reported repurchasing 104,022 of its own ordinary shares from 29 June to 3 July 2026 under a June 9, 2026 buyback program. Shares were bought across multiple trading venues at average prices around €26.24, totaling about €2.73m. As of 3 July 2026 close, it held 303,756 treasury shares.

Lakefront Biotherapeutics NV (LKFT) said it received a Belgian transparency notification from Madison Avenue Partners on June 24, 2026. Madison Avenue Partners and affiliates crossed above the 5% voting-rights threshold on June 15, 2026, holding 3,498,892 voting rights (5.31%) out of 65,897,071 shares.

Lakefront Biotherapeutics (Euronext & NASDAQ: LKFT) said it has launched a €50 million share repurchase program, allowing open-market purchases of ordinary shares through Dec. 31, 2026. The company will hold repurchased shares as treasury shares. The program was set up with Morgan Stanley & Co International PLC, and updates will be provided as required.

This article provides an in-depth analysis of Lakefront Biotherapeutics NV's (GLPG.F) leadership and management team, including compensation details for CEO Henry Gosebruch and recent changes to the executive and board members. It highlights several key appointments and departures, along with strategic developments such as the wind-down of cell therapy activities and updates on clinical trials for their CAR-T programs and TYK2 inhibitor. The company's market cap, management and board tenure, and analyst coverage are also detailed.

Bank of America Corporation and its affiliates have disclosed a 5.74% position in Galapagos (NASDAQ: GLPG), crossing the 5% major shareholding threshold under Belgian transparency rules. This stake, comprising both voting rights and equivalent financial instruments, was first surpassed on February 26, 2026, and adjusted by March 2, 2026. The holdings are distributed across various BofA entities and include instruments like rights to recall, physical call options, and swaps.

Galapagos has appointed Dr. Paulo Fontoura as a Non-Executive Independent Director, effective February 9, 2026, succeeding Dr. Susanne Schaffert. Dr. Fontoura brings extensive pharmaceutical leadership experience from Roche, and his appointment is expected to bolster Galapagos' strategic oversight as it advances innovative medicines and business development. Analysts currently rate GLPG stock as a Sell with a $22.00 price target, while TipRanks’ AI Analyst, Spark, assigns a Neutral rating due to challenging financial and operational landscapes despite a strong cash position.